Here's what we'll cover
Here's what we'll cover
If you've been paying full price for tirzepatide - the active ingredient in Mounjaro and Zepbound - because your CVS Caremark plan dropped it from coverage, you may be getting some welcome news. CVS has restored Eli Lilly's obesity medication to its formularies, a move that could meaningfully lower costs for a significant number of patients.
Here is what this development actually means for you, how to find out if you're affected, and what steps to take next.
What a Formulary Reversal Actually Means
A formulary is the list of drugs that an insurance plan agrees to cover, usually at a negotiated cost. When a drug gets removed from a formulary, patients either lose coverage entirely or get shifted to a higher cost tier, sometimes paying hundreds of dollars more per month.
When an insurer like CVS Caremark adds a drug back to the formulary, it signals that coverage terms have been renegotiated, typically involving rebates or pricing agreements between the pharmacy benefit manager and the drug manufacturer.
For patients, a formulary reinstatement can mean dropping from paying $500 to $1,000 per month out of pocket down to a much more manageable copay, sometimes as low as $25 to $50 depending on your specific plan tier.
Why CVS Removed It in the First Place
Pharmacy benefit managers (PBMs) like CVS Caremark regularly review their formularies and make coverage decisions based on negotiations with drugmakers, clinical evidence, and cost management goals. Lilly's obesity drugs - particularly tirzepatide - have been high-cost, high-demand medications since their approvals.
Formulary exclusions are often a negotiating lever. The reinstatement suggests Lilly and CVS reached updated terms that made coverage viable again for the insurer.
Which Patients Are Affected
Not every CVS Caremark plan works the same way. CVS Caremark manages pharmacy benefits for thousands of employer-sponsored plans, Medicare Part D plans, and commercial insurance products. Coverage decisions vary by plan type and employer.
Here is a rough breakdown of who might be affected:
The key point is that formulary updates at the PBM level do not automatically flow through to every individual employer plan. Your employer has its own contract with CVS Caremark and may or may not adopt the updated formulary.
How to Find Out If Your Coverage Has Changed
Do not assume your coverage has been restored just because of this news. Here are the steps to confirm your status.
Step 1: Check Your Plan's Current Formulary Online
Log into your CVS Caremark member portal or your insurance company's website. Most plans publish a real-time formulary search tool where you can look up a specific drug by name or NDC code.
Search for both tirzepatide (the generic name) and the brand names Mounjaro and Zepbound, since they are technically different FDA approvals - Mounjaro for type 2 diabetes and Zepbound for chronic weight management.
Step 2: Call Your Pharmacy Benefit Manager Directly
The phone number on the back of your insurance card connects you to your PBM or insurer. Ask specifically: "Has tirzepatide been added back to my plan's formulary for obesity treatment? What tier is it on? Is a prior authorization required?"
Getting this information verbally is not enough. Ask them to document it or send you written confirmation.
Step 3: Work With Your Prescribing Doctor
If coverage has been restored, your doctor may still need to submit a fresh prior authorization. Prior authorizations (PAs) are requests your physician sends to your insurance company proving that the medication is medically necessary for you. Many insurers require a PA for GLP-1 and dual GIP/GLP-1 medications even when they are on formulary.
Your doctor's office likely has experience with this process, but it helps to follow up proactively rather than waiting weeks for an answer.
What This Means for Tirzepatide Costs
Even with formulary coverage, costs can vary quite a bit. Here is a realistic picture of what patients typically pay at different coverage levels.
If your plan restores coverage but tirzepatide lands on a high cost-sharing tier, you may still want to stack a manufacturer savings card on top of your insurance. Lilly has offered savings programs for commercially insured patients, though eligibility rules apply. You can also explore GLP-1 Coupons to find current savings options.
The Bigger Picture: Why Formulary Decisions Matter So Much
This back-and-forth between insurers and drugmakers is not just corporate noise. For people managing obesity, these decisions directly control access to care.
Research consistently shows that tirzepatide produces substantial weight loss in clinical trials - 15% to 22% of body weight on average in the SURMOUNT trial series. But those results only help people who can actually afford and access the medication long term.
Formulary exclusions have been one of the biggest barriers to GLP-1 treatment access in the United States. When a plan drops a drug, many patients either pay out of pocket until they can't sustain it, switch to a less effective alternative, or stop treatment altogether.
What This Tells Us About the Obesity Treatment Landscape
CVS restoring coverage suggests that the business case for covering obesity medications is becoming harder to ignore. As clinical evidence mounts that treating obesity reduces downstream costs - hospitalizations, cardiovascular events, diabetes progression - more insurers are reconsidering earlier formulary exclusions.
This does not mean coverage battles are over. Employers still make individual formulary decisions, and coverage for obesity treatment remains inconsistent across the country. But the trend is moving in a more favorable direction for patients.
Should You Switch Plans or Providers Based on This?
If you have been managing the cost of Mounjaro through a telehealth provider or compounding pharmacy because your insurance would not cover it, it is worth reassessing your options now.
Some patients find that a combination of commercial insurance coverage plus a provider who helps navigate prior authorizations offers the best long-term cost structure. Others find telehealth providers who offer bundled pricing for the medication and clinical support to be more straightforward.
Comparing Best Providers side by side can help you figure out which path makes the most sense given your insurance situation, health goals, and budget.
No waiting list. No insurance needed.
Frequently Asked Questions
Does the CVS formulary change automatically restore my Mounjaro or Zepbound coverage?
Not necessarily. The formulary update applies at the PBM level, but individual employer plans may or may not adopt the change. You need to contact CVS Caremark or your HR department directly to confirm whether your specific plan now covers tirzepatide.
What is the difference between Mounjaro and Zepbound, and does coverage differ?
Both contain tirzepatide, but Mounjaro is FDA-approved for type 2 diabetes and Zepbound is FDA-approved for chronic weight management. Insurance plans often cover them differently - Mounjaro may be covered under diabetes benefits while Zepbound may fall under separate obesity treatment coverage, which many plans still exclude or limit.
Will I need a new prior authorization if coverage is restored?
Likely yes. Even after a formulary reinstatement, most insurance plans require a prior authorization for GLP-1 and GIP/GLP-1 medications. Your prescribing doctor needs to submit documentation showing medical necessity. Contact your doctor's office to initiate this process.
What if tirzepatide is back on formulary but I still can't afford the copay?
Eli Lilly offers a savings card program for commercially insured patients that may reduce your cost to as little as $25 per month. Income-based assistance programs also exist. Check the Lilly Cares Foundation and current GLP-1 coupon options for the most up-to-date savings tools.
Does this CVS formulary change affect Medicare patients?
Medicare Part D coverage is governed by separate rules and each plan has its own formulary. The CVS Caremark commercial formulary update may not apply to Medicare plans. Medicare patients should check their specific Part D plan's formulary directly or call 1-800-MEDICARE for guidance.
What should I do if my employer plan has not adopted the new formulary?
You can request that your HR or benefits administrator adopt the updated CVS Caremark formulary. You can also ask your doctor to submit a medical exception or appeal if the medication is denied. In the meantime, manufacturer savings cards and patient assistance programs may help bridge the cost gap.
What You Should Do Right Now
If you are currently taking or considering tirzepatide, this formulary news is worth acting on quickly. Coverage decisions at insurers can shift again, and the window to benefit from a reinstatement is best used proactively.
Here is a simple action plan:
- Log into your CVS Caremark portal and run a formulary search for tirzepatide, Mounjaro, and Zepbound.
- Call the member services number on your insurance card and ask explicitly about current formulary status and prior authorization requirements.
- Contact your doctor's office to let them know you want to pursue or resubmit a prior authorization if coverage has been restored.
- Compare your total monthly cost under insurance coverage versus current telehealth or cash-pay options. Sometimes the numbers are closer than you expect, and sometimes insurance coverage changes the equation significantly.
- Look into savings programs if your plan tier still leaves you with a high copay. Current offers are listed on the GLP-1 Coupons page.
The Bottom Line
CVS returning Lilly's obesity drug to its formulary is genuinely good news for patients, but it requires action on your part to actually benefit from it. Coverage is not restored automatically, and the details vary by plan.
The broader message here is that access to GLP-1 and GIP/GLP-1 treatments is continuing to improve, even if progress feels slow and uneven. Insurers are increasingly recognizing the clinical and economic case for covering obesity as the chronic disease it is.
If you have been delaying treatment because of cost concerns, or if you have been paying out of pocket while hoping your insurance would come around, now is a good time to revisit the question.
GLP-1.com is here to help you cut through the confusion. Whether you want to compare providers, check current pricing, or understand your treatment options, start with the Best Providers comparison tool or browse the latest GLP-1 Coupons to find savings that apply to your situation. As always, work with your physician before starting or changing any medication.